Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Pipeline Review, H2 2016', provides in depth analysis on Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted pipeline therapeutics. 

The report provides comprehensive information on the Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) 
- The report reviews Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) Overview 6
Therapeutics Development 7
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Products under Development by Stage of Development 7
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Products under Development by Therapy Area 8
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Products under Development by Indication 9
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Products under Development by Companies 12
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Companies Involved in Therapeutics Development 20
Bristol-Myers Squibb Company 20
Epigen Biosciences, Inc. 21
F. Hoffmann-La Roche Ltd. 22
Ono Pharmaceutical Co., Ltd. 23
RxBio, Inc. 24
Sanofi 25
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Drug Profiles 26
BMS-986020 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
BMS-986202 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
ITMN-10534 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Rx-100 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
SAR-100842 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small Molecules to Antagonize LPA1 Receptor for Metastatic Breast Cancer and Renal Fibrosis - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Small Molecules to Antagonize LPA1 Receptor for Pulmonary Fibrosis - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecules to Antagonize Lysophosphatidic Acid Receptor 1 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Dormant Projects 36
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Featured News & Press Releases 38
Sep 28, 2011: RxBio Receives $15m BARDA Contract For Development Of Rx100 To Protect Against Radiation 38
May 11, 2011: Amira To Present Preclinical Data On AM152 At Annual Meeting Of American Thoracic Society 38
May 02, 2011: Amira Pharmaceuticals Completes Phase I Clinical Study Of AM152 39
Apr 19, 2011: Amira Receives Orphan Drug Status For AM152 In Idiopathic Pulmonary Fibrosis 39
Oct 28, 2010: Amira Initiates Phase I Clinical Trial For AM152 39
Sep 27, 2010: Amira Submits AM152 IND To FDA For Potential Use In Fibrotic Diseases 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42

List of Tables

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 14
Number of Products by Stage and Mechanism of Action, H2 2016 16
Number of Products by Stage and Route of Administration, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 19
Pipeline by Bristol-Myers Squibb Company, H2 2016 20
Pipeline by Epigen Biosciences, Inc., H2 2016 21
Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 22
Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 23
Pipeline by RxBio, Inc., H2 2016 24
Pipeline by Sanofi, H2 2016 25
Dormant Projects, H2 2016 36
Dormant Projects (Contd..1), H2 2016 37